- JP-listed companies
- Oncolys BioPharma Inc.
Oncolys BioPharma Inc.JP:4588
Market cap
¥12B
P/E ratio
| Dec 31, 2012 | Dec 31, 2013 | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | |
| Net sales | 397 | 1 | 29 | 121 | 178 | 229 | 169 | 1,304 | 314 | 642 | 976 | 63 |
| Cost of service | - | - | - | - | - | 72 | 120 | 113 | 72 | 444 | 638 | 32 |
| Beginning finished goods inventory | 13 | 15 | 20 | 14 | 14 | 13 | 12 | 9 | 9 | 8 | 8 | 8 |
| Total | 15 | 20 | 20 | 14 | 14 | 15 | 12 | 9 | 14 | 8 | 8 | 8 |
| Finished goods transfer to other account | - | - | - | - | - | - | - | - | - | - | - | 8 |
| Ending finished goods inventory | 15 | 20 | 14 | 14 | 13 | 12 | 9 | 9 | 8 | 8 | 8 | - |
| Gross profit (loss) | 397 | 1 | 28 | 121 | 178 | 158 | 47 | 1,191 | 236 | 199 | 338 | 31 |
| Selling, general and administrative expenses | 538 | 667 | 856 | 1,073 | 1,040 | 1,236 | 1,295 | 1,702 | 1,911 | 1,653 | 1,543 | 1,961 |
| Operating profit (loss) | -141 | -665 | -828 | -952 | -861 | -1,078 | -1,248 | -511 | -1,675 | -1,455 | -1,205 | -1,930 |
| Interest income | 1 | 1 | 3 | 4 | 5 | 4 | 21 | 20 | 1 | 0 | 1 | 1 |
| Dividend income | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Subsidy income | 1 | 16 | 51 | 89 | 1 | - | - | - | - | - | - | 3 |
| Foreign exchange gains | 42 | 42 | 6 | - | - | - | - | - | - | 37 | 63 | 28 |
| Other | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | 1 | 0 | 0 |
| Non-operating income | 56 | 84 | 107 | 103 | 6 | 4 | 21 | 20 | 1 | 39 | 63 | 32 |
| Interest expenses | 8 | 3 | 5 | 4 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 |
| Amortization of restricted stock remuneration | - | - | - | - | - | - | - | 42 | 14 | 69 | 18 | 1 |
| Share acquisition rights issuance costs | - | - | - | - | - | - | - | - | 10 | 0 | - | 3 |
| Share issuance costs | 1 | 40 | 0 | - | - | - | - | - | 4 | 12 | 0 | 9 |
| Other | 1 | 1 | 0 | - | 1 | - | - | - | 0 | 0 | - | - |
| Non-operating expenses | 13 | 44 | 5 | 6 | 9 | 13 | 4 | 48 | 49 | 85 | 22 | 16 |
| Ordinary profit (loss) | -99 | -625 | -726 | -855 | -864 | -1,087 | -1,230 | -539 | -1,724 | -1,501 | -1,163 | -1,914 |
| Gain on transfer of receivables | - | - | - | - | - | - | - | - | - | - | 21 | - |
| Gain on sale of non-current assets | 0 | - | - | - | 0 | - | - | - | - | - | - | 0 |
| Extraordinary income | 75 | - | - | - | 0 | - | - | - | - | - | 21 | 0 |
| Impairment losses | - | 8 | - | - | 58 | - | - | - | 11 | 20 | 4 | 22 |
| Extraordinary losses | 77 | 8 | 11 | - | 64 | - | - | 369 | 368 | 111 | 4 | 22 |
| Profit (loss) before income taxes | -101 | -633 | -737 | -855 | -928 | -1,087 | -1,230 | -909 | -2,091 | -1,612 | -1,146 | -1,936 |
| Income taxes - current | 2 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 3 | 3 |
| Income taxes | 2 | 2 | 2 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 3 | 3 |
| Profit (loss) | - | - | - | -857 | -931 | -1,091 | -1,234 | -912 | -2,095 | -1,615 | -1,149 | -1,939 |